1. Vaccine composition against a malignant tumor for the treatment and / or prevention of malignant tumors accompanied by increased expression of the WT1 gene in positive for human leukocyte antigen (HLA) -A * 0206 individuals containing a protein that is a gene product of the tumor suppressor WT1, or incomplete peptide, where the incomplete protein is a polypeptide consisting of 7-30 consecutive amino acids, a modified WT1 peptide containing the same amino acid residues at positions 4-8 from the N-terminus as the peptide WT1 at the corresponding positions, or a modified WT1 peptide containing the same amino acid residues at positions 4-8 from the N-terminus as the WT1 peptide at the corresponding positions. 2. The composition of claim 1, wherein the protein, which is the gene product of the tumor suppressor WT1, is a protein selected from (a) or (b) :( a) a protein consisting of the amino acid sequence of SEQ ID NO: 1, or (b) a protein consisting of an amino acid sequence containing a deletion, substitution or addition of one to seven amino acids in the amino acid sequence (a), each of which is immunogenic for an HLA-A * 0206 positive individual. 3. The composition of claim 1, wherein the partial peptide is a WT1: Ser Leu Gly Glu Gln Gln Tyr Ser Val peptide (SEQ ID NO: 2), a WT1 peptide: Arg Met Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 3), WT1P1F peptide: Phe Leu Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 11), WT1P2M peptide: Ser Met Gly Glu Gln Gln Tyr Ser Val (SEQ ID NO: 16), WT1P3M peptide: Ser Leu Met Glu Gln Gln Tyr Ser Val (SEQ ID NO: 20), WT1P1F peptide: Phe Met Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 34), WT1P2L peptide: Arg Leu Phe Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 39), peptide WT1P3M: Arg Met Met Pro Asn Ala Pro Tyr Leu (SEQ ID NO: 46) or peptide WT1P9V: Arg Met Phe Pro Asn Ala Pro Tyr Val (SEQ ID NO: 49). 4. The composition of claim 1, wherein the partial peptide is co1. Вакцинная композиция против злокачественной опухоли для лечения и/или профилактики зло
